A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers

NCT01286103 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Canagliflozin 300 mg once daily and 150 mg twice daily
DRUG: Canagliflozin 100 mg once daily and 50 mg twice daily

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.